ABI - 医索

Safety, tolerability and efficacy of 21Pb-DOTAMTATE asa targeted alpha therapy for subjects with unresectableor metastatic somatostatin receptor-expressinggastroenteropancreatic neuroendocrine

医客学院 - 会议报告集

Randomized phase lllll trial of gemcitabine plusnab-paclitaxel versus. concurrentchemoradiotherapy with S-1 as neoadjuvanttreatment for borderline resectable pancreaticcancerGABARNANCE study

医客学院 - 会议报告集

SACI-0 HR A randomized phase ll trial ofsacituzumab govitecan with or without pembrolizumabin patients with metastatic hormone receptor-positive!HER2-negative breast cancer

医客学院 - 会议报告集

ACE-Breast-02 a pivotal phase lllll trial of ARX788, anovel anti-HER2 ADC, vs lapatinib plus capecitabine forHER2 advanced breast cancer

医客学院 - 会议报告集

Nivolumab plus ipilimumab vs chemotherapy as first-linetreatment for microsatellite instability-highmismatchrepairdeficient metastatic colorectal cancer expandedefficacy analysis from CheckMate 8HW

医客学院 - 会议报告集

Neoadjuvant treatment of lBl310 (anti-CTLA-4 antibody) plus sintilimab(anti-PD.1 antibody) in patients with microsatellite instabilityhighmismatchrepair-deficient colon cancer Results from a randomiz

医客学院 - 会议报告集

PROpel Phase III trial of olaparib and abiraterone versus placebo and abi as first-line therapy for patients with mCRPC

医客学院 - 会议报告集

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer an open-label, single-arm, phase II trial

医客学院 - 药物研究

百度以第一单位发表Nature！

百度，以第一完成单位的身份在《Nature》杂志发表论文了！国际顶级学术期刊《Nature》正刊发表了百度与合作单位在生物计算领域的重磅突破性成果——《Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity》，提.....

学术资讯 - 热点资讯

刚刚！迈瑞进入全球械企TOP30

能够撼动全球医疗器械行业格局的要素：新冠疫情、大额并购、分拆独立、监管升级等几乎是最大变量。而这些在风云变幻的2022年全球医疗器械市场，几乎时时刻刻都在发生。2022年，强生以166亿收购Abiomed，成为2022年度医疗器械领域的最大并.....

学术资讯 - 热点资讯